HIV is a lentivirus and attacks immune system which leads to death. The continuous research has developed treatment for HIV which has made a separate market for HIV drugs. The HIV drug market is increasing due to increasing awareness and diagnosis rates. There are around five million people in low and middle income countries who do not have access to AIDS drugs. HIV is very common in Southern African region. Botswana and Zimbabwe are the most affected countries; HIV is the most underlying reason for more than one third of all deaths among children under age of five.

In Japan, unwanted teen pregnancy is rising which may drive HIV drugs market in near future. Also the innovation of new drugs is driving HIV market; research continues to remain a significant unmet medical need for effective treatment.

The report outlines major countries affected from HIV virus and death rates. It also gives an overview of HIV virus and therapies in demand. The report presents overview of global market, HIV in US, UK, Asia and Sub-Saharan Africa. It highlights major markets for HIV drugs with overall market value and major drugs revenue.

The report discusses the opportunities prevailing in the HIV drugs market and issues affecting the growth. It also talks about competition prevalent in the market. It profiles major players with an overview of their business, key financials and business strategies.

1. Industry Overview
1.1 Introduction
1.2 Treatment for HIV

2. Market Size
2.1 Global HIV Market
HIV/AIDS Cases
2.2 United States
HIV/AIDS Cases by Region
AIDS Diagnoses
2.3 Sub-Saharan Africa
2.4 United Kingdom
Diagnosed Cases
HIV Infected Persons by Region
2.5 Asia

3. HIV Drugs Market
Market Value
Drug Revenue Comparison

4. Market Trends
4.1 Opportunities in HIV Drug Market
Opportunities in Japan
Increasing Number of Cases Leads to Increase in Drug Demand
Increasing Demand of Sexual Health Services
4.2 Key Issues
Policy & Programme Development
Capacity of Communities
Raising Awareness
Gender Issues

5. Major Market Players
5.1 Competition
Major Players Growth Comparison
5.2 Company Profiles
5.2.1 Gilead Science
Overview
Business Strategies
Maintaining Leadership in HIV/AIDS Treatment
Expanded Product Portfolio
Strategic Partnerships
5.2.2 Idenix Pharmaceuticals
Overview
Business Strategies
Restructuring Program
Strong Patent Portfolio
5.2.3 Bristol Myers Squibb
Overview
Business Strategies
Productivity Transformation Initiative

6. Market Forecast
People Receiving Therapy Projections

List of Tables
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (PIs)
HIV/AIDS Worldwide Cases/Deaths (2007)
US AIDS Diagnosis (2006)
Transmission Category of HIV (2006)
Sub-Saharan Africa Cases/Deaths (2007)
HIV/AIDS Diagnosed Cases in UK by Gender (2000-08)
HIV/AIDS Diagnosed Cases in UK by Region (2000-08)
China AIDS Statistics (2007)
Major Players Growth Comparison (2007)
Gilead Revenue by Geography (2005-07)
Idenix Revenue by Products (2006-07)
Bristol-Myers Squibb Revenue by Business Segments (2005-07)
First-line Therapy Projections (2008-13E)
People Receiving Antiretroviral Therapy (2006-08E)

List of Charts
Worldwide HIV/AIDS Cases (2006)
Children Living with HIV Globally (2007)
Top Ten Reported AIDS Cases in US by Region (2006)
HIV Prevalence in Pakistan by Region (2007)
Global HIV Drugs Market (2004-07)
Global HIV Drugs Revenue Comparison (2006)
Global HIV Drugs Revenue Comparison (2007)
Ranking of America’s Largest Pharma Corporations (2007)
Top Biotechnology Companies (2006)